These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 20495920

  • 21. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
    Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F.
    Clin Cancer Res; 2013 Jul 01; 19(13):3508-19. PubMed ID: 23695170
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
    Xu R, Shen H, Guo R, Sun J, Gao W, Shu Y.
    Biomed Pharmacother; 2012 Jul 01; 66(5):384-9. PubMed ID: 22560634
    [Abstract] [Full Text] [Related]

  • 24. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH.
    J Clin Oncol; 2004 Mar 01; 22(5):785-94. PubMed ID: 14990633
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
    Cheng H, An SJ, Dong S, Zhang YF, Zhang XC, Chen ZH, Jian-Su, Wu YL.
    J Hematol Oncol; 2011 Jan 21; 4():5. PubMed ID: 21255411
    [Abstract] [Full Text] [Related]

  • 28. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
    Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jänne PA.
    Cancer Res; 2004 Oct 15; 64(20):7241-4. PubMed ID: 15492241
    [Abstract] [Full Text] [Related]

  • 29. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY, Zhao MB, Zhuang GB, Li PP.
    Lung Cancer; 2012 Jan 15; 75(1):30-7. PubMed ID: 21757251
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, Kuwano M, Ono M.
    Cancer Res; 2005 May 15; 65(10):4253-60. PubMed ID: 15899817
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
    Park JS, Jun HJ, Cho MJ, Cho KH, Lee JS, Zo JI, Pyo H.
    Clin Cancer Res; 2006 Aug 15; 12(16):4989-99. PubMed ID: 16914589
    [Abstract] [Full Text] [Related]

  • 37. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ.
    Lung Cancer; 2009 Jul 15; 65(1):80-4. PubMed ID: 19059670
    [Abstract] [Full Text] [Related]

  • 38. Combined effects of resveratrol and paclitaxel on lung cancer cells.
    Kubota T, Uemura Y, Kobayashi M, Taguchi H.
    Anticancer Res; 2003 Jul 15; 23(5A):4039-46. PubMed ID: 14666716
    [Abstract] [Full Text] [Related]

  • 39. A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
    Zhang L, Qi Y, Xing K, Qian S, Zhang P, Wu X.
    Oncol Rep; 2018 Aug 15; 40(2):1046-1054. PubMed ID: 29917169
    [Abstract] [Full Text] [Related]

  • 40. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.
    Clin Cancer Res; 2011 Apr 15; 17(8):2260-9. PubMed ID: 21220474
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.